腹腔镜与开腹手术在新辅助化疗后卵巢癌减瘤术中的比较
基于美国国家癌症数据库2010至2012年IIIC和IV期上皮性卵巢癌接受新辅助化疗及间隔减瘤术的患者,比较腹腔镜与开腹手术的3年生存率、住院时间、围手术期死亡、再入院及残留病灶。腹腔镜组3年生存率47.5%与开腹组52.6%无显著差异(P=.12),腹腔镜组术后住院中位4天较开腹组5天略短(P<.001),再入院率、90天内死亡及减瘤不满意率均无显著差异。
要点
- 腹腔镜与开腹间隔减瘤术的3年生存率分别为47.5%和52.6%,无显著差异(P=.12)。
- 腹腔镜组术后住院中位4天,较开腹组5天略短(P<.001)。
- 再入院率、90天内死亡及减瘤不满意率两组无显著差异。
核心结论
- 接受新辅助化疗后选择腹腔镜间隔减瘤术的卵巢癌患者,3年生存率与开腹间隔减瘤术者相似。
- 腹腔镜手术与术后住院时间略短相关,而再入院率和围手术期死亡风险两种手术相似。
研究设计与样本
- 利用美国国家癌症数据库识别2010至2012年诊断为IIIC和IV期上皮性卵巢癌、接受新辅助化疗和间隔减瘤术的患者队列。
- 比较腹腔镜与开腹间隔减瘤术患者的3年总生存、术后住院时间、术后90天死亡和残留病灶状态。
- 生存分析采用Kaplan-Meier法和Cox回归模型,主要分析为意向性治疗。
- 在显著性水平.05下,本研究有80%把握度检测3年生存率8%的差异。
主要发现
- 共识别3071例符合纳入标准的女性,其中450例(15%)手术以腹腔镜开始。
- 腹腔镜组3年生存率47.5%(95%CI 41.4-53.5)与开腹组52.6%(95%CI 50.3-55.0)无差异(P=.12)。
- 调整人口学特征、机构类型、合并症和分期后生存仍无差异(调整HR 1.09;95%CI 0.93-1.28;P=.26)。
- 腹腔镜组术后住院中位4天,开腹组5天(P<.001)。
- 再入院率腹腔镜组5.3% vs 开腹组3.7%(P=.26),术后90天内死亡2.8% vs 2.9%(P=.93),减瘤不满意20.6% vs 22.6%(P=.29),均无显著差异。
临床怎么用
- 原文结论为:新辅助化疗后选择腹腔镜间隔减瘤术的卵巢癌患者3年生存率与开腹手术者相似,腹腔镜与术后住院时间略短相关,再入院率和围手术期死亡风险相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare 3-year survival, length of hospitalization, perioperative mortality, risk of readmission, and residual disease associated with laparoscopic and laparotomic interval debulking surgery among women with epithelial ovarian cancer. METHODS: We used the National Cancer Database to identify a cohort of patients diagnosed with stage IIIC and IV epithelial ovarian cancer between 2010 and 2012 who underwent neoadjuvant chemotherapy and interval debulking surgery. We compared 3-year overall survival, duration of postoperative hospitalization, 90-day postoperative mortality, and residual disease status between women who underwent interval debulking by laparoscopy and by laparotomy. We used the Kaplan-Meier method and Cox regression models in survival analyses. At a significance of .05, this study had 80% power to detect an 8% difference in 3-year survival. The main analysis was intention to treat. RESULTS: We identified 3,071 women meeting inclusion criteria, of whom 450 (15%) underwent surgery initiated laparoscopically. There was no difference in 3-year survival between patients undergoing laparoscopy [47.5%; 95% confidence interval (CI) 41.4-53.5] and laparotomy (52.6%; 95% CI 50.3-55.0; P=.12). Survival did not differ after adjustment for demographic characteristics, facility type, presence of comorbidities, and stage (adjusted hazard ratio, 1.09; 95% CI 0.93-1.28; P=.26). Postoperative hospitalization was slightly shorter in the laparoscopy group (median 4 compared with 5 days, P<.001). Frequency of readmission (5.3% compared with 3.7%; P=.26), death within 90 days of surgery (2.8% compared with 2.9%, P=.93), and suboptimal debulking (20.6% compared with 22.6%, P=.29) did not differ between patients undergoing laparoscopy and laparotomy. CONCLUSION: Ovarian cancer patients selected for laparoscopic interval debulking surgery after neoadjuvant chemotherapy have 3-year survival rates similar to women who undergo interval debulking by laparotomy. Laparoscopy is associated with a modestly shorter postoperative hospitalization, whereas readmission rates and risk of perioperative death are similar for the surgeries.
引用
- Melamed A, Nitecki R, Boruta DM, et al. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Obstet Gynecol. 2017. PMID: 28383367. doi:10.1097/AOG.0000000000001851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。